GAMMA Investing’s Cartesian Therapeutics RNAC Stock Holding History

GAMMA Investing’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.96K	Buy	827 +622	+303%	+$5.42K	﹤0.01%	3578
2026 Q2	$2.14K	Sell	205 -607	-75%	-$4.5K	﹤0.01%	3722
2026 Q1	$4.99K	Buy	+812	New	+$5.78K	﹤0.01%	3360
2025 Q4	–	Sell	-15	Closed	-$153	–	4129
2025 Q3	$153	Hold	15	–	–	﹤0.01%	3813
2025 Q2	$156	Buy	15 +6	+67%	+$64	﹤0.01%	3734
2025 Q1	$119	Buy	+9	New	+$161	﹤0.01%	3777

Other funds holding RNAC

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

GAMMA Investing's RNAC Position: Q3 2026 in Review

GAMMA Investing increased its Cartesian Therapeutics (RNAC) stake by 303% in Q3 2026, buying an estimated $5.42K and bringing the position to 827 shares worth $5.96K. The position accounts for ﹤0.01% of the portfolio, ranked #3578.

GAMMA Investing first reported a position in RNAC in Q1 2025 and has held it in 6 quarters since. 6 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

GAMMA Investing held 827 shares of Cartesian Therapeutics worth $5.96K as of Q3 2026.
GAMMA Investing bought 622 Cartesian Therapeutics shares in Q3 2026, an estimated $5.42K.
Cartesian Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3578 holding.
GAMMA Investing first reported a position in Cartesian Therapeutics in Q1 2025 and has held it in 6 quarters since.
6 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.